Enanta Pharmaceuticals (ENTA) Share-based Compensation Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.62% |
| Dec 31, 2025 | -4.84% |
| Sep 30, 2025 | -3.19% |
| Jun 30, 2025 | -2.56% |
| Mar 31, 2025 | -1.19% |
| Dec 31, 2024 | 2.14% |
| Sep 30, 2024 | 11.33% |
| Jun 30, 2024 | 5.40% |
| Mar 31, 2024 | 3.39% |
| Dec 31, 2023 | 6.75% |
| Sep 30, 2023 | 10.32% |
| Jun 30, 2023 | 11.70% |
| Mar 31, 2023 | 15.45% |
| Dec 31, 2022 | 11.62% |
| Sep 30, 2022 | 16.31% |
| Jun 30, 2022 | 19.64% |
| Mar 31, 2022 | 13.13% |
| Dec 31, 2021 | 13.16% |
| Sep 30, 2021 | 16.35% |
| Jun 30, 2021 | 17.26% |
| Mar 31, 2021 | 17.26% |
| Dec 31, 2020 | 19.64% |
| Sep 30, 2020 | 21.43% |
| Jun 30, 2020 | 24.59% |
| Mar 31, 2020 | 28.33% |
| Dec 31, 2019 | 37.75% |
| Sep 30, 2019 | 41.51% |
| Jun 30, 2019 | 39.94% |
| Mar 31, 2019 | 44.31% |
| Dec 31, 2018 | 74.71% |
| Sep 30, 2018 | 70.41% |
| Jun 30, 2018 | 75.90% |
| Mar 31, 2018 | 69.45% |
| Dec 31, 2017 | 71.10% |
| Sep 30, 2017 | 67.56% |
| Jun 30, 2017 | 100.81% |
| Mar 31, 2017 | 157.24% |